Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents

Journal of Medicinal Chemistry

Volumn 43, Issue 16, 2000, Pages 3168-3185

  Khanna, I K ^a   Yu, Y ^a   Huff, R M ^a   Weier, R M ^a   Xu, X ^a   Koszyk, F J ^a   Collins, P W ^a   Cogburn, J N ^a   Isakson, P C ^a   Koboldt, C M ^a   Masferrer, J L ^a   Perkins, W E ^a   Seibert, K ^a   Veenhuizen, A W ^a   Yuan, J ^a   Yang, D C ^a   Zhang, Y Y ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIARYLIMIDAZOLE DERIVATIVE; 4 [2 (2 METHYLTHIAZOL 4 YL) 4 (TRIFLUOROMETHYL) 1H IMIDAZOL 1 YL]BENZENESULFONAMIDE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; INFLAMMATORY DISEASE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOGS; EDEMA; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERALGESIA; IMIDAZOLES; INTESTINES; ISOENZYMES; MEMBRANE PROTEINS; MICE; NITRILES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; RATS; STOMACH; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0034632752     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0000719     Document Type: Article

References (59)

1. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs
2. Prostaglandins in peptic ulcer disease. An overview of current status and future directions
3. Mechanisms of nonsteroidal antiinflammatory drug induced gastric damage
4. The clinical significance of inhibition of renal prostaglandin synthesis
5. Renal syndromes associated with nonsteroidal antiinflammatory drugs
6. Sulindac: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases
7. Inhibition of prostaglandin synthesis by sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate dihydrate (CS-600), a new antiinflammatory drug, and its active metabolite in vitro and in vivo
8. Nabumetone: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases
9. Aspirin prodrugs: Synthesis and hydrolysis of 2-benzyloxy-2-methyl-4h-1,3-benzodioxin-4-ones
10. A clinical trial comparing a new NSAID (droxicam) and piroxicam in spinal osteoarthritis
11. Chemische struktur und antiphlogisistische wirkung in der reihe der substituierten indol-3-essigsauren
12. Nonsteroidal antiinflammatory drugs (NSAIDS) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury
13. Pharmaceutical composition
14. Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
15. Antiinflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor
16. Meloxicam
17. Antiinflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal antiinflammatory agent with favorable gastrointestinal tolerance
18. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
19. Aspirin selectivity inhibits prostaglandin production in human platelets
20. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1
21. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases
22. 2 synthase (cyclooxygenase) in human monocytes
23. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
24. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
25. Expression of a mitogen-response gene encoding prostaglandin synthase is regulated by mRNA splicing
26. TIS10, a phorbol ester tumor promoter-inducible mRNA from swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue
27. A serum and glucocorticoid regulated 4-kilobase m-RNA encodes a cyclooxygenase related protein
28. Synthesis and biological evaluation of 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of SC-58635 (celecoxib)
29. Celecoxib
30. The discovery of rofecoxib. [MK-996, vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone]. An orally active cyclooxygenase-2 inhibitor
31. 1,2-diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents
32. 1,2-diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2
33. 1,2-diarylcyclopentenes as selective cyclooxygease-2 inhibitors and orally active antiinflammatory agents
34. 2-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxide useful as an anxiolytic agent
35. Lithiation of methoxypyridines directed by a-amino alkoxides
36. Preparation of heteroarenecarbonitriles by reaction of heteroarene n-oxides with trimthylsilyl cyanide in the presence of DBU
37. Site-selectivity in the cyanation of 3-substituted pyridine 1-oxides with trimethylsilan-ecarbonitrile
38. Preparation of 2-imidazole and 2-thia-zolecarbaldehyde
39. Synthesis of 4-cyano-oxazole
40. Anomalous metalation behavior in 1,3-oxazoles. Alkylation of 2-methyl-4-carboxyoxazoles via the cornforth intermediate
41. A novel one-pot conversion of methyl sulfones to sulfonamides
42. Method of preparing sulfonamides from sulfones
43. Use of 2,5-dimethylpyr-role as an amino-protecting group in an efficient synthesis of 5-amino-3-[(n-methylpyrrolidin-(2R)-yl)methy]indole
44. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase
45. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain
46. Carrageenan induced edema in hind paw of the rat as an assay for antiinflammatory drugs
47. New and sensitive methods for measuring thermal nociception in cutaneous hyperalgesia
48. The effect of immunomodulating drugs on adjuvant induced arthritis in lewis rats
49. Selective cyclooxygenase inhibitors: Novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors
50. 1,2-diarylspiro[2,4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: Synthesis and structure- activity relationships
51. 1,2-diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active antiinflammatory agents
52. A general synthesis of substituted fluorenones and azafluorenones
53. Dihalomalonaldehydes
54. 2-methoxyallyl bromide. A superior acetonyl alkylating agent